Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Roivant Cuts Jobs, Reallocates Staff As It Prepares To Put New Stars In The Spotlight

Business development idea and developing industry success through creative invention as a light bulb evolving to a gear shape as a 3D illustration.

Related Content

Axovant's Cupboard Is Bare After Lead Dementia Program Fails

Jan 09 2018

Takeda Continues To Shed Pipeline Assets In Roivant Deal

Jun 07 2016

AbbVie's Got A Competitive Edge With Elagolix For Women With Uterine Fibroids

Feb 21 2018

Deal Watch: Allogene Gets Pfizer's Off-The-Shelf CAR-T Program, $300m Series A Backing

Apr 03 2018

Nabriva On Pace For Lefamulin NDA; Stock Tumbles Despite Trial Success

May 21 2018

Finance Watch: Roivant Raises $1.1bn, Relying On Private Equity To Fund New Companies

Aug 14 2017

Takeda Paves The Way For Myovant With Phase III Fibroid Success

Oct 03 2017

Deal Watch: Merck KGAA, Pfizer, eFFECTOR Agree To PD-L1/MNK Combo Study In CRC

Jun 27 2017

Tech Transfer Roundup: Aduro Hopes Stanford Algorithm Will Optimize Its IO Candidates

Feb 10 2017

Related Companies

Roivant Sciences Ltd.

Sio Gene Therapies, Inc.

Myovant Sciences Ltd.

Roivant Sciences Ltd.

Enzyvant Therapeutics, Inc.

Urovant Sciences, Inc.

Roivant Sciences Ltd.

Roivant Sciences Ltd.

Roivant Sciences Ltd.

Pharmasset, Inc.

Gilead Sciences, Inc.

Medivation, Inc.

Duke University School of Medicine

Takeda Pharmaceutical Co. Ltd.

AbbVie Inc.

Merck & Co., Inc.

Nabriva Therapeutics plc.

Additional Topics

Business Strategies Companies Deals Commercial BioPharmaceutical

More from Strategy

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window